Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

被引：2

作者：

Chowdhury, S. ^{[1
,2
]}

Patnaik, A. ^{[3
]}

Campbell, D. ^{[4
]}

Shapiro, J. ^{[5
]}

Bryce, A. H. ^{[6
]}

McDermott, R. ^{[7
]}

Sautois, B. ^{[8
]}

Vogelzang, N. J. ^{[9
]}

Bambury, R. ^{[10
]}

Voog, E. ^{[11
]}

Zhang, J. ^{[12
]}

Green, M. ^{[13
]}

Beltman, J. ^{[14
]}

Despain, D. ^{[15
]}

Simmons, A. D. ^{[16
]}

Watkins, S. P. ^{[17
]}

Golsorkhi, A. ^{[18
]}

Xiao, J. ^{[19
]}

Abida, W. ^{[20
]}

机构：

[1] Guys Hosp, Med Oncol, London, England

[2] Sarah Cannon Res Inst, London, England

[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA

[4] Univ Hosp Geelong, Barwon Hlth, Med Oncol, Geelong, Vic, Australia

[5] Cabrini Hosp, Med Oncol, Malvern, Australia

[6] Mayo Clin, Hematol & Med Oncol, Phoenix, AZ USA

[7] Adelaide & Meath Hosp Natl Childrens Hosp, Genitourinary Oncol, Dublin, Ireland

[8] CHU Sart Tilman, Liege Univ Hosp, Med Oncol, Liege, Belgium

[9] Comprehens Can Ctr Nevada, Med Oncol, Las Vegas, NV USA

[10] Cork Univ Hosp, Med Oncol, Cork, Ireland

[11] Clin Victor Hugo Ctr Jean Bernard, Med Oncol, Le Mans, France

[12] H Lee Moffitt Canc Ctr & Res Inst, Genitourinary Oncol, Tampa, FL USA

[13] Certara Strateg Consulting, Integrated Drug Dev, Menlo Pk, CA USA

[14] Clovis Oncol Inc, Regulatory Affairs, Boulder, CO USA

[15] Clovis Oncol Inc, Biostat, Boulder, CO USA

[16] Clovis Oncol Inc, Translat Med, Boulder, CO USA

[17] Clovis Oncol UK Ltd, Clin Sci, Cambridge, England

[18] Clovis Oncol Inc, Clin Dev, Boulder, CO USA

[19] Clovis Oncol Inc, Clin & Nonclin Pharmacol, Boulder, CO USA

[20] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.918

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

659P

引用

页码：S533 / S534

页数：2

共 50 条

[31] Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study
Kotani, Naoki
Wilkins, Justin J.
Wade, Janet R.
Dang, Steve
Sutaria, Dhruvitkumar S.
Yoshida, Kenta
Sundrani, Sameer
Ding, Hao
Garcia, Josep
Hinton, Heather
Sane, Rucha
Chanu, Pascal
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (06) : 511 - 521
[32] Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.
Jose Mendez-Vidal, Maria
Lozano, Rebeca
Castro, Elena
Romero-Laorden, Nuria
Rodriguez-Vida, Alejo
Lainez, Nuria
Hernandez, Amaia
Villatoro, Rosa
Zambrana, Francisco
Villa Guzman, Jose Carlos
Garcia Dominguez, Rocio
Galvan Ruiz, Saray
Escribano, Ricardo
Gallardo Diaz, Enrique
Querol, Rosa
Luque, Raquel
Gonzalez del Alba, Aranzazu
Puente, Javier
Olmos, David
Lorente, David
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33] Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US
Shore, N.
Laliberte, F.
Ionescu-Ittu, R.
Gayle, A.
Amin, S.
Yang, L.
Payne, S.
Mahendran, M.
Lejeune, D.
Yu, L.
Burgents, J.
Duh, M. S.
Ghate, S.
ANNALS OF ONCOLOGY, 2020, 31 : S534 - S535
[34] Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients.
Rao, Arpit
Ryan, Charles J.
Morris, David
Assikis, Vasileios
Jha, Gautam
Ablaza, Adriel-John
Habeck, Jenn
Loehr, Andrea
Xiao, Jim
Gangolli, Esha A.
CANCER RESEARCH, 2021, 81 (13)
[35] Sequencing of chemotherapy and androgen-axis inhibitors (AAIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Dhawan, Ravinder
Yang, Tony
Miao, Raymond
Hennessy, Daniel
Sonpavde, Guru
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[36] Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Perez-Ruixo, Carlos
Ackaert, Oliver
Ouellet, Daniele
Chien, Caly
Uemura, Hiroji
Olmos, David
Mainwaring, Paul
Lee, Ji Youl
Yu, Margaret K.
Perez-Ruixo, Juan Jose
Smith, Matthew R.
Small, Eric J.
CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4460 - 4467
[37] BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC)
Hadfield, Matthew J.
De Souza, Andre
Golijanin, Dragan
Wood, Roxanne
Olszewski, Adam
Holder, Sheldon L.
El-Deiry, Wafik S.
Aggarwal, Rahul
Mega, Anthony
Carneiro, Benedito A.
CANCER RESEARCH, 2023, 83 (08)
[38] COST-EFFECTIVENESS OF OLAPARIB COMPARED TO RUCAPARIB FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN UNITED STATES
Ghule, P.
Kohli, M.
Malone, D. C.
Nelson, R. E.
VALUE IN HEALTH, 2022, 25 (07) : S428 - S429
[39] BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
De Souza, Andre
Aggarwal, Rahul
Safran, Howard
Golijanin, Dragan
Wood, Roxanne
Olszewski, Adam
El-Deiry, Wafik S.
Mega, Anthony
Carneiro, Benedito A.
CANCER RESEARCH, 2021, 81 (13)
[40] Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Posadas, Edwin M.
Chit, Kim N.
de Wit, Ronald
de Jonge, Maja J. A.
Attard, Gerhardt
Friedlander, Terence
Yu, Margaret
Hellemans, Peter
Chien, Caly
Abrams, Charlene
Gonzalez, Martha
Trudel, Geralyn C.
Chauhan, Vijay
Saad, Fred
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →